Wealth Enhancement Advisory Services LLC Invests $870,000 in Regeneron Pharmaceuticals Inc (REGN) Stock

Share on StockTwits

Wealth Enhancement Advisory Services LLC bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, HoldingsChannel reports. The fund bought 2,528 shares of the biopharmaceutical company’s stock, valued at approximately $870,000.

A number of other institutional investors have also recently bought and sold shares of REGN. Whittier Trust Co. increased its holdings in Regeneron Pharmaceuticals by 195.7% during the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 45 shares during the period. Smithfield Trust Co. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $27,000. Rehmann Capital Advisory Group grew its stake in Regeneron Pharmaceuticals by 1,700.0% in the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 68 shares in the last quarter. AdvisorNet Financial Inc grew its stake in Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $29,000. 67.03% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.42% of the stock is currently owned by corporate insiders.

A number of equities analysts have commented on REGN shares. TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price target for the company in a research note on Friday, January 4th. Cowen reissued a “hold” rating and issued a $385.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $441.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $413.94.

Shares of Regeneron Pharmaceuticals stock traded up $0.59 during trading on Friday, reaching $336.00. The company’s stock had a trading volume of 21,916 shares, compared to its average volume of 748,061. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $442.00. The stock has a market capitalization of $36.65 billion, a price-to-earnings ratio of 16.99, a price-to-earnings-growth ratio of 1.33 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same quarter in the prior year, the company earned $5.23 EPS. The firm’s revenue was up 21.9% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Wealth Enhancement Advisory Services LLC Invests $870,000 in Regeneron Pharmaceuticals Inc (REGN) Stock” was originally reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2019/05/03/wealth-enhancement-advisory-services-llc-invests-870000-in-regeneron-pharmaceuticals-inc-regn-stock.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Diversification

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.